Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Sensipar Approved; Target U.S. Market At Least 300,000 Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Cinacalcet is indicated for the treatment of hyperparathyroidism associated with kidney disease and hypercalcemia in parathyroid cancer patients.

You may also be interested in...



Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market

Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.

Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation

NICE determination limits recommended use to severe refractory SHPT patients.

Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation

NICE determination limits recommended use to severe refractory SHPT patients.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel